All In Biotech

Drug Trial Radar · NCT02183025

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

Double Blind Study to Evaluate Efficacy and Safety of Meloxicam 7.5 mg and 15 mg Versus Mefenamic Acid 1500 mg in the Treatment of Dysmenorrhea

Last checked: Nov 20, 2026Latest source record: Aug 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 337 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

337

Actual

Start

Jan 1998

Primary completion

Apr 1999

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea

Conditions

  • Dysmenorrhea

Interventions

  • Meloxicam 7.5 mgDrug

  • Meloxicam 15 mgDrug

  • Mefenamic acid 500 mgDrug

  • Placebo matching 7.5 mg meloxicamDrug

  • Placebo matching 15 mg meloxicamDrug

  • Placebo matching 500 mg mefenamic acidDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of severity of lumbar and/or abdominal pain on a visual analogue scale (VAS)Time frame: Baseline and day 3-5 of each treatment cycle

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.